buy office 2007 student license graphisoft archicad 12 buy adobe illustrator cc 2014 mac prices buying acrobat 9 pro buy adobe incopy cc 2014 mac software buy windows 7 student product key cheapest vmware fusion 2.0 purchase adobe photoshop cs4 canada purchase and download windows 7 online cheapest windows xp pro sp3 buy outlook online photoshop elements price buy adobe illustrator 9 price of windows 7 business edition in india cheap microsoft word download buying 2007 outlook buy adobe acrobat standard discount office 2011 mac best buy microsoft publisher 2007 buy windows xp 64 bit sp2 buy microsoft office 2008 mac business buy filemaker server 8 buy partition magic 6.0 cheap outlook 2007 buying indesign adobe cheap autodesk inventor software autocad lt 2009 price purchase adobe creative suite cs2 cheap windows xp professional software buy buy windows xp licence key

Lymphoseek designated fast track status in head and neck cancer

Wed, Dec 11, 2013

Oral Cancer News

Source: www.empr.com
Author: press release

Navidea announced that the FDA has granted Fast Track designation to Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymposeek Injection was evaluated in a prospective, open-label, multicenter, within-patient study (NEO3-06). It was designed to identify sentinel lymph nodes (SLNs) and determine the false negative rate (FNR) associated with Lymphoseek-identified SLNs relative to the pathological status of non-SLNs in head and neck and intraoral squamous cell carcinoma. The primary endpoint for the NEO3-06 trial was based on the number of subjects with pathology-positive lymph nodes following a multiple level lymph node dissection. A minimum of 38 subjects whose lymph nodes contained pathology-confirmed disease was required. Thirty nine subjects out of over 80 subjects enrolled were determined to have pathology-positive lymph nodes.

Navidea intends to file the supplemental New Drug Application (sNDA) for Lymphoseek before the end of 2013. Lymphoseek is already approved for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.